4//SEC Filing
Rosen Robert 4
Accession 0000899243-22-029674
CIK 0000920465other
Filed
Aug 23, 8:00 PM ET
Accepted
Aug 24, 8:27 PM ET
Size
24.7 KB
Accession
0000899243-22-029674
Insider Transaction Report
Form 4
Rosen Robert
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−18,000→ 0 totalExercise: $8.52→ Common Stock (18,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−10,000→ 0 totalExercise: $28.24→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−10,000→ 0 totalExercise: $19.19→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−12,000→ 0 totalExercise: $3.93→ Common Stock (12,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−10,000→ 0 totalExercise: $19.69→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−10,000→ 0 totalExercise: $28.10→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−30,000→ 0 totalExercise: $4.53→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−12,000→ 0 totalExercise: $5.99→ Common Stock (12,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-08-22−30,000→ 0 totalExercise: $4.81→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time").
- [F2](Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Documents
Issuer
LA JOLLA PHARMACEUTICAL CO
CIK 0000920465
Entity typeother
Related Parties
1- filerCIK 0001555089
Filing Metadata
- Form type
- 4
- Filed
- Aug 23, 8:00 PM ET
- Accepted
- Aug 24, 8:27 PM ET
- Size
- 24.7 KB